- ►diabetesjournals.org T Danne, RHA Becker, T Heise, C Bittner, AD … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS—For insulin glulisine versus RHI, maximum insulin concentrations (58
vs. 33 μIU/ml, P < 0.05) and initial insulin concentrations (insulin [area
under the curve] AUC 0–2h 5,232 vs. 2,994 μIU · min −1 · ml −1 , P ... Cited by 46 - Related articles - BL Direct - All 7 versions
- ►naturalis.nl [PDF] RP Hoogma, D Schumicki - Hormone and metabolic research, 2006 - thieme-connect.com This twelve-week, European, multicenter, controlled, open-label, randomized (1 :
1), parallel-group trial compared the safety of insulin glulisine with insulin
aspart used in continuous subcutaneous insulin infusion. Patients with type ... Cited by 24 - Related articles - BL Direct - All 7 versions
M Dreyer, R Prager, A Robinson, K Busch, G … - Hormone and metabolic research= Hormon-und …, 2005 - ncbi.nlm.nih.gov Insulin glulisine (glulisine), a human insulin analogue with a rapid-acting
time-action profile, has been developed to fulfil the mealtime (bolus) insulin
requirement in patients with diabetes. The aim of this multinational, multi- ... Cited by 39 - Related articles - BL Direct - All 5 versions
RH Becker, AD Frick, F Burger, H Scholtz, JH … - Experimental and clinical endocrinology & diabetes: …, 2005 - ncbi.nlm.nih.gov Insulin glulisine is a new rapid-acting insulin analog. The aim of this study
was to assess the glucodynamic efficacy of insulin glulisine compared with
regular human insulin (RHI) using a manual euglycemic clamp technique. ... Cited by 23 - Related articles - All 4 versions
- ►diabetesjournals.org K Rave, O Klein, AD Frick, RHA Becker - Diabetes Care, 2006 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—In a single-dose, randomized, four-way complete
cross-over study, subjects received standardized, 15-min meals, covered by
subcutaneous injections of either insulin glulisine (immediately premeal or ... Cited by 28 - Related articles - BL Direct - All 6 versions
RH Becker, AD Frick, F Burger, JH Potgieter, … - Experimental and clinical endocrinology & diabetes: …, 2005 - ncbi.nlm.nih.gov AIMS/HYPOTHESIS: This study compared the pharmacokinetics and pharmacodynamics
of insulin glulisine, insulin lispro, and regular human insulin in obese
subjects. METHODS: In this single-dose, randomized, double-blind, crossover ... Cited by 43 - Related articles - BL Direct - All 5 versions
- Free from Publisher G Dailey, J Rosenstock, RG Moses, K Ways - Diabetes care, 2004 - Am Diabetes Assoc RESULTS—A slightly greater reduction from baseline to end point of HbA 1c was
seen in the glulisine group versus RHI (−0.46 vs. −0.30% with RHI; P =
0.0029). Also, at end point, lower postbreakfast (156 vs. 162 mg/dl [8.66 ... Cited by 104 - Related articles - BL Direct - All 7 versions
SK Garg, J Rosenstock, K Ways - Endocrine Practice, 2005 - AACE The Diabetes Control and Complications Trial showed that intensified glycemic
control reduces the risk of developing the late complications of diabetes (1,2).
Traditionally, fasting plasma glucose and glycated hemo- globin (as A1c ... Cited by 63 - Related articles - All 2 versions
[CITATION] Evaluation of the pharmacodynamic and pharmacokinetic profiles of insulin glulisine-a …
